相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest
Damian Szklarczyk et al.
NUCLEIC ACIDS RESEARCH (2023)
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants
Daniel Hirschhorn et al.
CELL (2023)
IL-17 and IL-17-producing cells in protection versus pathology
Kingston H. G. Mills
NATURE REVIEWS IMMUNOLOGY (2023)
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
RAF-MEK-ERK pathway in cancer evolution and treatment
Rahim Ullah et al.
SEMINARS IN CANCER BIOLOGY (2022)
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy
Lars Michel et al.
EUROPEAN HEART JOURNAL (2022)
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Yared Hailemichael et al.
CANCER CELL (2022)
Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors
Paulien Kaptein et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Persister state-directed transitioning and vulnerability in melanoma
Heike Chauvistre et al.
NATURE COMMUNICATIONS (2022)
Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy
Tobias Hoch et al.
SCIENCE IMMUNOLOGY (2022)
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Jan C. Brase et al.
CLINICAL CANCER RESEARCH (2021)
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Paula Voabil et al.
NATURE MEDICINE (2021)
IL-17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art
Nicoletta Bernardini et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)
Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies
Jose Maria G. Ruiz de Morales et al.
AUTOIMMUNITY REVIEWS (2020)
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial
Alexander M. M. Eggermont et al.
JAMA ONCOLOGY (2020)
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Paolo Antonio Ascierto et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S. Grasso et al.
CANCER CELL (2020)
IL-17-Producing Cells in Tumor Immunity: Friends or Foes?
Da-Sol Kuen et al.
IMMUNE NETWORK (2020)
Locally Targeting the IL-17/IL-17RA Axis Reduced Tumor Growth in a Murine B16F10 Melanoma Model
Ya-Shan Chen et al.
HUMAN GENE THERAPY (2019)
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Tuba N. Gide et al.
CANCER CELL (2019)
WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs
Yuxing Liao et al.
NUCLEIC ACIDS RESEARCH (2019)
Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
Mingjia Li et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients
Alessio Cortellini et al.
SEMINARS IN ONCOLOGY (2019)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
David Liu et al.
NATURE MEDICINE (2019)
Th17 Cells Paradoxical Roles in Melanoma and Potential Application in Immunotherapy
Chen Chen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Perturbation-response genes reveal signaling footprints in cancer gene expression
Michael Schubert et al.
NATURE COMMUNICATIONS (2018)
The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments
Cristina Vajaitu et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model
Jake Wang et al.
PIGMENT CELL & MELANOMA RESEARCH (2017)
IL-17RC is critically required to maintain baseline A20 production to repress JNK isoform-dependent tumor-specific proliferation
Chi Yan et al.
ONCOTARGET (2017)
xCell: digitally portraying the tissue cellular heterogeneity landscape
Dvir Aran et al.
GENOME BIOLOGY (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors
Hojabr Kakavand et al.
CLINICAL CANCER RESEARCH (2017)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations
Katrina Meeth et al.
PIGMENT CELL & MELANOMA RESEARCH (2016)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Th17 Cell Plasticity and Functions in Cancer Immunity
Leslie Guery et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Regulation of IL-17 in autoimmune diseases by transcriptional factors and microRNAs
Deena Khan et al.
FRONTIERS IN GENETICS (2015)
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Ahmad A. Tarhini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Helen Rizos et al.
CLINICAL CANCER RESEARCH (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Primary tumor versus metastasis: new experimental models for studies on cancer cell homing and metastasis in melanoma
Iris Helfrich et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Georgina V. Long et al.
NATURE COMMUNICATIONS (2014)
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Gabriela Bindea et al.
IMMUNITY (2013)
Targeting IL-17and TH17 cells in chronic inflammation
Pierre Miossec et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis
Rajkumar Noubade et al.
BLOOD (2011)
Th17 cells in cancer: help or hindrance?
Cailin Moira Wilke et al.
CARCINOGENESIS (2011)
Functional Specialization of Interleukin-17 Family Members
Yoichiro Iwakura et al.
IMMUNITY (2011)
Endogenous IL-17 contributes to reduced tumor growth and metastasis
Ilona Kryczek et al.
BLOOD (2009)
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
Natalia Martin-Orozco et al.
IMMUNITY (2009)
Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice
Jean M. Daley et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer
Antoni Ribas et al.
ONCOLOGIST (2007)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
RL Camp et al.
CLINICAL CANCER RESEARCH (2004)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
分享论文
